Buclizine

Pediatric
  • TRADE NAMES: Aphilan; Bucladin-S; Buclixin; Longifene; Odetin; Postafeno; Vibazina; Vibazine
  • INDICATIONS: Motion sickness, nausea/vomiting
  • CLASS: Histamine H1 receptor antagonist
  • HALF-LIFE: N/A
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Aprobarbital, Butabarbital, Chloral Hydrate, Ethchlorvynol, Mephobarbital, Pentobarbital, Phenobarbital, Phenothiazines, Primidone, Secobarbital, Zolpidem

PREGNANCY CATEGORY: C

Our database has 0 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe



Page last updated 08/02/2021

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top